A new inhaler that treats chronic obstructive pulmonary disease (COPD) and also helps reduce environmental harm has been approved for use in the UK. This inhaler is already available in India.
Inhalers are the frontline treatment for asthma and COPD, but they come with a steep environmental cost, according to a new UCLA Health study - the largest to date quantifying inhaler-related ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the world’s first low-carbon version of a triple-combination inhaler for chronic obstructive pulmonary disease (COPD). The ...
Inhalers are the frontline treatment for asthma and COPD, but they come with a steep environmental cost, according to a new UCLA Health study — the largest to date quantifying inhaler-related ...
Asthma inhalers are critical for delivering small amounts of medication to people's lungs to improve breathing and help prevent asthma attacks, but those tiny puffs add up to a large environmental ...
Inhalers that deliver quick relief to patients with asthma and chronic obstructive pulmonary disease (COPD) may be taking a toll on the planet, producing as much climate-warming pollution as more than ...
Miami (June 17, 2025) – Digital inhalers may help predict impending acute exacerbations of chronic obstructive pulmonary disease (COPD), according to a new study. The study is published in the May ...
The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...
Inhalers that provide fast-acting treatment for people with certain respiratory conditions are contributing to greenhouse gas emissions, which can worsen both climate change and the conditions ...
Hosted on MSN
What's New in COPD Treatment?
The symptoms of COPD aren’t always obvious. Subtle signs like finding it harder to keep up with friends on a walk or unconsciously cutting down on physical activity can be easy to miss. Some people ...
Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback